Literature DB >> 8781889

In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin against Streptococcus pneumoniae as determined by three quantitative methods.

A L Barry1, S D Brown, P C Fuchs.   

Abstract

E-test, broth microdilution, and agar dilution susceptibility tests were used to evaluate penicillin and five extended-spectrum cephalosporins against 196 strains of Streptococcus pneumoniae with different levels of penicillin resistance. Oxacillin disk tests corresponded to minimum inhibitory concentrations of penicillin determined by the E-test better than those generated by broth microdilution or agar dilution methods. Relative potency of the study drugs was as follows: cefotaxime = ceftriaxone > penicillin > cefuroxime > ceftizoxime > ceftazidime.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8781889     DOI: 10.1007/bf01695670

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

Review 2.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

3.  Screening pneumococci for penicillin resistance.

Authors:  J M Swenson; B C Hill; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

Review 4.  Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.

Authors:  C C John
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

5.  Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  J H Jorgensen; J M Swenson; F C Tenover; M J Ferraro; J A Hindler; P R Murray
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

Review 6.  Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview.

Authors:  F Baquero
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

7.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

8.  Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test.

Authors:  J H Jorgensen; M J Ferraro; M L McElmeel; J Spargo; J M Swenson; F C Tenover
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

9.  In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

Authors:  A L Barry; M A Pfaller; P C Fuchs; R R Packer
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.

Authors:  C W Stratton; K E Aldridge; M S Gelfand
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

View more
  1 in total

Review 1.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.